Related Experiment Videos
Effects of prostaglandin E1 on collagen diseases with high levels of circulating immune complexes
T Yoshikawa1, H Suzuki, H Kato
1First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, School of Medicine, Japan.
Insights
Prostaglandin E1 (PGE1) effectively reduced circulating immune complexes (CIC) in four patients with collagen diseases. This treatment also improved peripheral vascular disorders, including skin ulcers and finger necrosis.
Area of Science:
- Rheumatology
- Immunology
- Vascular Medicine
Background:
- Collagen diseases, such as systemic sclerosis and lupus erythematosus, often present with high levels of circulating immune complexes (CIC).
- Elevated CIC are associated with disease activity and peripheral vascular complications.
Observation:
- Four patients with collagen diseases (progressive systemic sclerosis, systemic lupus erythematosus, polyarteritis nodosa, rheumatoid arthritis) and high CIC levels were treated.
- Prostaglandin E1 (PGE1) was administered via continuous central venous infusion at 10 ng/kg/min for 72 hours.
Findings:
- All four patients exhibited a significant decrease in CIC levels post-PGE1 administration.
- One patient with progressive systemic sclerosis experienced complete healing of a skin ulcer.
- One patient with rheumatoid arthritis showed improvement in finger necrosis.
Implications:
- Continuous intravenous Prostaglandin E1 infusion demonstrates efficacy in reducing CIC levels in patients with collagen-related autoimmune diseases.
- PGE1 treatment may offer therapeutic benefits for associated peripheral vascular manifestations, such as ulcers and necrosis.
- Further research into PGE1 as a treatment for immune complex-mediated conditions and vascular complications is warranted.
Abstract:
Prostaglandin E1 (PGE1) was administered to 4 patients with collagen diseases presenting with high levels of circulating immune complexes (CIC) in sera. Our study patients had progressive systemic sclerosis, systemic lupus erythematosus, polyarteritis nodosa, and rheumatoid arthritis. In all 4 patients, CIC levels significantly decreased after administration of PGE1 by continuous infusion at 10/ng/kg/min via central venous catheter for 72 h. In addition, the skin ulcer in a patient with PSS healed completely, and the finger necrosis in a patient with RA improved. These results suggest that PGE1 given by continuous venous infusion is effective in reducing CIC, in addition to improving peripheral vascular disorders.